Cardio-oncology & otherCohort study
Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights
- Prospective cohort study
- single-centre
- observational
Authors' conclusion
This study revealed that 16-38% of patients with haematologic malignancies and breast cancer developed CTR-CVT during follow-up, in which patients with high/very high risk were well predicted by the HFA-ICOS risk assessment tool.
Study context
- Population
- Patients aged ≥20 years with haematologic malignancies or breast cancer receiving anticancer agents, Kurume University Hospital, October 2016 to August 2021
- Participants
- 486 patients
- Exposure
- Leukaemia vs Malignant lymphoma vs Multiple myeloma vs Breast cancer
- Outcome
- CV adverse events, CTCAE v4.0 Grade ≥2
Main finding
As reported in the abstract
CV adverse events
Observational data: associations, not effects.
Secondary outcomes
Cardiovascular (CV) death · during follow-up
- CV death
- 4 (0.8%)
Original publication
Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights. Eur J Prev Cardiol. Published 23 June 2023. doi:10.1093/eurjpc/zwad210
Summarised from the published abstract; every number is checked against it